Taro Pharmaceuticals Inc

🇨🇦Canada

Country: 🇨🇦Canada

Ownership: -

Employees: -

Market Cap: $1.6B

Website

Clinical Trials

Study Comparing Adapalene and Benzoyl Peroxide Gel 0.1%/2.5% to Epiduo® and Both to a Placebo Control in the Treatment of Acne Vulgaris

Phase 1

Completed

Conditions: Acne Vulgaris

Interventions: Drug: Placebo
Drug: Epiduo® Gel
Drug: Adapalene and Benzoyl Peroxide Gel 0.1%/2.5%

First Posted Date: 2012-12-05

Last Posted Date: 2017-05-04

Lead Sponsor: Taro Pharmaceuticals USA

Target Recruit Count: 2008

Registration Number: NCT01742637

Evaluate the Clinical Equivalence of Two Naftifine HCl 1% Creams in Patients With Interdigital Tinea Pedis

Phase 1

Completed

Conditions: Tinea Pedis

Interventions: Drug: Naftifine HCl Cream 1%
Drug: Naftin® (Naftifine HCl) Cream 1%
Drug: Placebo topical cream

First Posted Date: 2012-04-19

Last Posted Date: 2014-05-06

Lead Sponsor: Taro Pharmaceuticals USA

Target Recruit Count: 1053

Registration Number: NCT01580891

Evaluate the Safety & Bioequivalence of a Generic Butenafine Cream & Lotrimin Ultra® & Compare Both to a Vehicle Control in Treatment of Interdigital Tinea Pedis

Phase 1

Completed

Conditions: Tinea Pedis

Interventions: Drug: Butenafine Vehicle
Drug: Lotrimin Ultra®
Drug: Butenafine Hydrochloride Cream, 1%

First Posted Date: 2012-04-19

Last Posted Date: 2017-05-05

Lead Sponsor: Taro Pharmaceuticals USA

Target Recruit Count: 707

Registration Number: NCT01580878

A Therapeutic Equivalence Study of Two Oxiconazole Nitrate Topical Cream Treatments for Patients With Tinea Pedis

Phase 1

Completed

Conditions: Tinea Pedis

Interventions: Drug: Oxiconazole Nitrate Cream 1%
Drug: Oxiconazole Nitrate Cream 1% (Oxistat®)
Drug: Placebo

First Posted Date: 2012-01-27

Last Posted Date: 2014-01-22

Lead Sponsor: Taro Pharmaceuticals USA

Target Recruit Count: 661

Registration Number: NCT01519752

A Therapeutic Equivalence Study of Two Metronidazole 1%Topical Gel Treatments for Patients With Rosacea

Phase 1

Completed

Conditions: Rosacea

Interventions: Drug: Metronidazole Topical Gel 1%
Drug: Placebo
Drug: Metronidazole Topical Gel 1% (Metrogel)

First Posted Date: 2012-01-20

Last Posted Date: 2013-12-23

Lead Sponsor: Taro Pharmaceuticals USA

Target Recruit Count: 602

Registration Number: NCT01513863

Locations: 🇺🇸
Investigator Site, West Jordan, Utah, United States

Effects of Desoximetasone Spray 0.25% in Patients With Moderate to Severe Plaque Psoriasis

Phase 3

Completed

Conditions: Psoriasis

Interventions: Drug: Desoximetasone Spray 0.25%
Drug: placebo

First Posted Date: 2010-09-22

Last Posted Date: 2014-07-03

Lead Sponsor: Taro Pharmaceuticals USA

Target Recruit Count: 120

Registration Number: NCT01206660

Locations: 🇺🇸
Investigator Site, Hazleton, Pennsylvania, United States

Effects of Desoximetasone Spray 0.25% on Moderate to Severe Plaque Psoriasis

Phase 3

Completed

Conditions: Psoriasis

Interventions: Drug: Desoximetasone Spray 0.25%
Drug: placebo comparator

First Posted Date: 2010-09-21

Last Posted Date: 2017-06-05

Lead Sponsor: Taro Pharmaceuticals USA

Target Recruit Count: 120

Registration Number: NCT01206387

Clinical Equivalence of Two Generic Butenafine Hydrochloride 1% Creams as Compared to Lotrimin Ultra Cream in Patients With Interdigital Tinea Pedis

Phase 1

Terminated

Conditions: Interdigital Tinea Pedis

Interventions: Drug: Butenafine Hydrochloride 1%
Drug: Butenafine Hydrochloride 1% B
Drug: Vehicle A
Drug: Vehicle B

First Posted Date: 2010-05-10

Last Posted Date: 2014-05-06

Lead Sponsor: Taro Pharmaceuticals USA

Target Recruit Count: 428

Registration Number: NCT01119742

Desoximetasone Spray 0.25%, Hypothalamic Pituitary Adrenal (HPA) Axis Study

Phase 2

Completed

Conditions: Psoriasis

Interventions: Drug: Desoximetasone 0.25% spray

First Posted Date: 2010-01-06

Last Posted Date: 2014-06-02

Lead Sponsor: Taro Pharmaceuticals USA

Target Recruit Count: 24

Registration Number: NCT01043393

Locations: 🇺🇸
Investigator Site, Simpsonville, South Carolina, United States

Desoximetasone Spray 0.05%, 0.25%; Dose Ranging Study

Phase 2

Completed

Conditions: Psoriasis

Interventions: Drug: Desoximetasone 0.05% once daily
Drug: Desoximetasone 0.25% once daily
Drug: Vehicle twice daily
Drug: Desoximetasone 0.05% twice daily
Drug: Vehicle once daily

First Posted Date: 2009-11-23

Last Posted Date: 2014-08-05

Lead Sponsor: Taro Pharmaceuticals USA

Target Recruit Count: 151

Registration Number: NCT01018134

Locations: 🇺🇸
Investigator Site, Simpsonville, South Carolina, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy